Pharma BD Deal Intelligence
The Xarelto windfall masked a costly, only partially digested consolidation whose pipeline engine has now gone quiet
Full analysis, sources & comparables →"It is thus worthwhile for Schering shareholders to accept our offer," said Bayer Management Board Chairman Werner Wenning, framing the takeover as central to…
"German company Bayer has all but completed its takeover of specialty pharmaceutical concern Schering AG, holding 92.4% of the latter's shares" — short of the…
"With the assistance of KPMG Deutsche Treuhand-Gesellschaft Aktiengesellschaft Wirtschaftsprufungsgesellschaft, Bayer has determined the adequate cash…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Squeeze-out completing 2006 takeover of Schering AG. Bayer Schering Pharma AG fully integrated 2007. EUR 14.6B headline. Source: Wikipedia, BioSpace, Bayer history.
The Xarelto windfall masked a costly, only partially digested consolidation whose pipeline engine has now gone quiet
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Schering AG (residual squeeze-out) (this deal) | 2007 | $985M | 69 |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
| Bayer AG / Asklepios BioPharmaceuticals | 2020 | $2.0B | 49 |
← Browse all deals · How we score deals
More: 2007 deals · Bayer AG deals